Welcome to the latest edition of the JITC digest. If any of our readers will be in New Orleans next month for the 2022 American Association for Cancer Research (AACR) Annual Meeting, we hope you will stop by the SITC booth in the exhibition hall for an opportunity to interact in person with JITC Deputy Editor-in-Chief Dr. James L. Gulley during one of our two Meet the Editor Sessions scheduled for 11:50 a.m.–12:20 p.m. on Monday, April 11 and Tuesday, April 12.
If you won’t be traveling to AACR, you can always take a virtual trip back in time with our popular archive articles, spotlighting important publications from the journal’s recent past.
Of course, the main attraction for the JITC digest is the exciting new papers in the current issue. This month we have two original research articles and a short report from the Clinical/Translational Cancer Immunotherapy section as well as original research from the Immunotherapy Biomarkers section.
Martina Svenja Lutz and colleagues describe a new mechanism of tumor immune escape from bispecific antibody treatment mediated by platelet activation.
A pan-cancer predictor for immune-related toxicity after anti-PD-1 monotherapy based on germline variants in microRNAs and their targets is identified by Joanne Weidhaas et al.
Treatment with anti-CCR4 leads to regulatory T cell depletion and meaningful tumor control in a canine clinical trial enrolling dogs with spontaneous prostate cancer reported by Shingo Maeda and colleagues.
Dipti Thakkar and colleagues demonstrate tumor control and microenvironment remodeling in multiple models with a first-in-class rationally targeted and non-depleting IgG4 isotype anti-VISTA antibody. After reading this comprehensive and meticulous work, be sure to continue your reading on VISTA and other promising targets in JITC’s Immune Checkpoints Beyond PD-1 Series.
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
